{"pmid":32349928,"pmcid":"PMC7180366","title":"Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.","text":["Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic.","Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guerin should be made during the current pandemic to limit the risk of contamination.","Eur Urol","Louis, Lenfant","Thomas, Seisen","Yohann, Loriot","Morgan, Roupret","32349928"],"abstract":["Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guerin should be made during the current pandemic to limit the risk of contamination."],"journal":"Eur Urol","authors":["Louis, Lenfant","Thomas, Seisen","Yohann, Loriot","Morgan, Roupret"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32349928","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.eururo.2020.04.039","topics":["Prevention"],"weight":1,"_version_":1666138495703318528,"score":9.490897,"similar":[{"pmid":32327396,"pmcid":"PMC7152883","title":"COVID-19 and Bacillus Calmette-Guerin: What is the Link?","text":["COVID-19 and Bacillus Calmette-Guerin: What is the Link?","The debate around the role of vaccination with Bacillus Calmette-Guerin has revived right in the time of the Coronavirus disease 19 pandemic. Since Bacillus Calmette-Guerin is one of the most commonly delivered therapies in urology, in this editorial we discuss some points that we think will be of interest and guidance to practicing urologists during this public health emergency.","Eur Urol Oncol","Hegarty, Paul K","Sfakianos, John P","Giannarini, Gianluca","DiNardo, Andrew R","Kamat, Ashish M","32327396"],"abstract":["The debate around the role of vaccination with Bacillus Calmette-Guerin has revived right in the time of the Coronavirus disease 19 pandemic. Since Bacillus Calmette-Guerin is one of the most commonly delivered therapies in urology, in this editorial we discuss some points that we think will be of interest and guidance to practicing urologists during this public health emergency."],"journal":"Eur Urol Oncol","authors":["Hegarty, Paul K","Sfakianos, John P","Giannarini, Gianluca","DiNardo, Andrew R","Kamat, Ashish M"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327396","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.euo.2020.04.001","topics":["Prevention"],"weight":1,"_version_":1666138494622236674,"score":356.90497},{"pmid":32420947,"title":"Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).","text":["Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).","Since the beginning of the COVID-19 epidemic, a possible explanation for the high heterogeneity of infection/mortality rates across involved countries was hinted in the prevalence of tuberculosis vaccination with Bacille Calmette-Guerin (BCG). A systematic review was therefore performed on May 2, 2020. A total of 13 articles were ultimately retrieved, 12 of them as preprint papers. All articles were ecological studies of low quality. Most of them did not include main confounding factors (i.e. demographic of the assessed countries, share of peo- ple residing in urban settings, etc.), and simply assessed the differences among incidence/mortality of COVID-19 with vaccination rates or by having vs. having not any vaccination policy for BCG. Even though all studies shared the very same information sources (i.e. international registries for BCG vaccination rates and open source data for COVID-19 epidemics), results were conflicting, with later studies apparently denying any true correlation between COVID-19 occurrence and BCG vaccination rates and/or policies. As a consequence, there is no sound evidence to recommend BCG vaccination for the prevention of COVID-19.","Acta Biomed","Ricco, Matteo","Gualerzi, Giovanni","Ranzieri, Silvia","Bragazzi, Nicola Luigi","32420947"],"abstract":["Since the beginning of the COVID-19 epidemic, a possible explanation for the high heterogeneity of infection/mortality rates across involved countries was hinted in the prevalence of tuberculosis vaccination with Bacille Calmette-Guerin (BCG). A systematic review was therefore performed on May 2, 2020. A total of 13 articles were ultimately retrieved, 12 of them as preprint papers. All articles were ecological studies of low quality. Most of them did not include main confounding factors (i.e. demographic of the assessed countries, share of peo- ple residing in urban settings, etc.), and simply assessed the differences among incidence/mortality of COVID-19 with vaccination rates or by having vs. having not any vaccination policy for BCG. Even though all studies shared the very same information sources (i.e. international registries for BCG vaccination rates and open source data for COVID-19 epidemics), results were conflicting, with later studies apparently denying any true correlation between COVID-19 occurrence and BCG vaccination rates and/or policies. As a consequence, there is no sound evidence to recommend BCG vaccination for the prevention of COVID-19."],"journal":"Acta Biomed","authors":["Ricco, Matteo","Gualerzi, Giovanni","Ranzieri, Silvia","Bragazzi, Nicola Luigi"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420947","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.23750/abm.v91i2.9700","topics":["Treatment"],"weight":1,"_version_":1667254896784572416,"score":153.61977},{"pmid":32455894,"title":"Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach.","text":["Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach.","The recent novel coronavirus, named coronavirus disease 2019 (COVID-19), has developed into an international pandemic affecting millions of individuals with hundreds of thousands of deaths worldwide. The highly infectious nature and widespread prevalence of this disease create a new set of obstacles for the bladder cancer community in both delivering and receiving care. In this manuscript, we address the unique issues regarding treatment prioritization for the patient with bladder cancer and how we at City of Hope have adjusted our clinical practices using a team-based approach that utilizes shared decision making with all stakeholders (physicians, patients, caregivers) to optimize outcomes during this difficult time. In addition to taking standard precautions for minimizing COVID-19 risk of exposure for those entering a healthcare facility (screening all personnel upon entry and donning facemasks at all times), we suggest the following three measures: (1) delay post-treatment surveillance visits until there is a decrease in local COVID-19 cases, (2) continue curative intent treatments for localized bladder cancer with COVID-19 precautions (i.e., choosing gemcitabine/cisplatin (GC) over dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC) neoadjuvant chemotherapy), and (3) increase the off-treatment period between cycles of palliative systemic therapy in metastatic urothelial carcinoma patients.","J Clin Med","Wang, Tina","Liu, Sariah","Joseph, Thomas","Lyou, Yung","32455894"],"abstract":["The recent novel coronavirus, named coronavirus disease 2019 (COVID-19), has developed into an international pandemic affecting millions of individuals with hundreds of thousands of deaths worldwide. The highly infectious nature and widespread prevalence of this disease create a new set of obstacles for the bladder cancer community in both delivering and receiving care. In this manuscript, we address the unique issues regarding treatment prioritization for the patient with bladder cancer and how we at City of Hope have adjusted our clinical practices using a team-based approach that utilizes shared decision making with all stakeholders (physicians, patients, caregivers) to optimize outcomes during this difficult time. In addition to taking standard precautions for minimizing COVID-19 risk of exposure for those entering a healthcare facility (screening all personnel upon entry and donning facemasks at all times), we suggest the following three measures: (1) delay post-treatment surveillance visits until there is a decrease in local COVID-19 cases, (2) continue curative intent treatments for localized bladder cancer with COVID-19 precautions (i.e., choosing gemcitabine/cisplatin (GC) over dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC) neoadjuvant chemotherapy), and (3) increase the off-treatment period between cycles of palliative systemic therapy in metastatic urothelial carcinoma patients."],"journal":"J Clin Med","authors":["Wang, Tina","Liu, Sariah","Joseph, Thomas","Lyou, Yung"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32455894","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/jcm9051574","keywords":["covid-19","bladder cancer","team-based medicine","urothelial carcinoma"],"topics":["Prevention"],"weight":1,"_version_":1667967698969034752,"score":133.67088},{"pmid":32356225,"title":"Intravesical therapy for bladder cancer in the pandemic of Covid-19.","text":["Intravesical therapy for bladder cancer in the pandemic of Covid-19.","World J Urol","Teoh, Jeremy Y C","Roupret, Morgan","Shariat, Shahrokh F","Herrmann, Thomas","32356225"],"journal":"World J Urol","authors":["Teoh, Jeremy Y C","Roupret, Morgan","Shariat, Shahrokh F","Herrmann, Thomas"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356225","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s00345-020-03218-8","topics":["Prevention"],"weight":1,"_version_":1666138495189516288,"score":118.72888},{"pmid":32406253,"title":"Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?","text":["Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?","Future Oncol","O'Connor, Ellen","Teh, Jiasian","Kamat, Ashish M","Lawrentschuk, Nathan","32406253"],"journal":"Future Oncol","authors":["O'Connor, Ellen","Teh, Jiasian","Kamat, Ashish M","Lawrentschuk, Nathan"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32406253","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.2217/fon-2020-0381","keywords":["bcg vaccine","covid-19","clinical trials","coronavirus","immunotherapy","mycobacterium bovis"],"topics":["Treatment"],"weight":1,"_version_":1666802845540679680,"score":117.10085}]}